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domains. Problems with physical component of QoL increased
with BMI increase, while for “pain/discomfort” and
“anxiety/depression”, normal weight and severe obese people
complained more than overweight and obese people. CON-
CLUSIONS: obesity is expensive for the health care system and
society and compromises individuals’ QoL. Policy makers should
pay attention to identiﬁcation, promotion and implementation
of programs aimed at preventing obesity.
OSTEOPOROSIS
OSTEOPOROSIS—Cost Studies
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OBJECTIVE: Hip fracture rates in Taiwan have been reported
to be higher than other Asian countries. The objective of this
analysis was to assess the cost-effectiveness of risedronate 
compared to alendronate in high-risk osteoporotic patients in
Taiwan. METHODS: A fracture-incidence based Markov model
of osteoporosis, where patients transition across states, was used
to estimate cost per fracture averted and cost per QALY gained.
The population included 1000 women aged 65 years with low
bone density and previous vertebral fracture, treated over a life-
time with either risedronate or alendronate. Model inputs spe-
ciﬁc to Taiwan included general population hip fracture rates,
mortality rates, health utilities, and relative risk reduction of
fracture with therapy (from published studies). The launch price
of risedronate was anticipated as 20% higher than alendronate
(risedronate: 16,394NT$/year; risedronate 13,662NT$/year).
Vertebral fracture rates were not available for Taiwan, thus inci-
dence rates were based on US ratios of hip to vertebral fracture.
The cost of fracture was included only for ﬁrst year after frac-
ture since chronic treatment is not routine in Taiwan. RESULTS:
There were 58 fewer hip fractures, 35 fewer vertebral fractures
and 52 more QALYs with risedronate compared to alendronate.
The fracture costs were 15% lower for patients treated with rise-
dronate, however total costs (including drug costs) were higher
(259,358NT$ [risedronate] vs. 227,296NT$ [alendronate]). The
incremental cost was 343,225NT$ (8400€) per any fracture
averted, 552,787NT$ (13,500€) per hip fracture averted, and
617,934NT$ (15.100€) per QALY gained for risedronate com-
pared to alendronate. CONCLUSIONS: Risedronate treatment
for high-risk osteoporotic women may represent a cost-effective
strategy for improving care of patients in Taiwan, despite the fact
that there are fewer downstream costs for treatment of chronic
fracture-related disability.
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OBJECTIVE: Osteoporosis and its related fractures are a major
source of illness and costs. Approximately 2 million post-
menopausal women have osteoporosis in France, resulting in an
annual cost of 1€ billion. This study assessed the clinical and eco-
nomic impact of risedronate therapy in a population of women
with post-menopausal osteoporosis (PMO) using a computer
simulation model. METHODS: A fracture incidence based
Markov model of osteoporosis, where patients transition across
outcome states over time, was used to estimate the incremental
cost per fracture prevented and the cost per QALY gained. The
analysis was conducted for a cohort of women aged 70 years
with low bone mineral density and prevalent vertebral fracture.
The impact of risedronate was assessed over 10 years, with
patients treated for the ﬁrst 5 years. Analyses used French epi-
demiological and cost data (from published literature). Relative
risk reductions with risedronate were set at 60% for hip fracture
and 41% for vertebral fracture. RESULTS: When added costs
are expressed per unit of beneﬁt gained, the results were approx-
imately 15,861€ per hip fracture prevented and 4351€ per 
QALY gained. Without treatment, 760 radiographic vertebral
fractures and 104 hip fractures occurred in a cohort of 1000
patients. Treatment with risedronate reduced the fractures occur-
ring during the treatment period, resulting in a smaller number
of fractures over 10 years: 604 vertebral fractures and 77 hip
fractures. If the analysis were extended to the entire PMO 
population in France, treatment with risedronate could result 
in a reduction of 312,000 vertebral fractures and 54,000 hip
fractures over 10 years. CONCLUSIONS: Analysis on a popu-
lation level demonstrates the magnitude of fractures and the cost
savings that could be averted among French women. Using
country-speciﬁc data, simulation models can provide realistic
estimates of the impact of disease and treatment costs in a 
population.
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OBJECTIVES: This study assesses disease burden and treatment
costs in patients with Paget’s Disease (PD) compared with a
matched comparator group (MC). METHODS: This is an obser-
vational study using 2001–2002 MarketScan Research databases
(MEDSTAT, Ann Arbor, MI), which consist of medical claims,
prescriptions and encounter data on 2 million active and retired
USA employees. Details include age, gender, drugs prescribed,
medical services rendered, ICD-9 diagnostic codes and costs. We
linked annual ﬁles to create a longitudinal panel with 24 months
of observation. Persons with PD were identiﬁed by ICD-9 code
731.0. A MC was selected using gender, age and risk adjustment
score, which was derived from a DCG/HCC classiﬁcation system
based on presence of 189 medical conditions. In this analysis, we
calculated the prevalence of 30 conditions linked to PD and total
costs for all medical care. The prevalence of co-morbidities and
health care costs were compared in PD and MC, and differences
tested using chi-square and t-tests, as appropriate. RESULTS:
Our study identiﬁed 488 individuals, 244 with PD and 244
matched comparators (MC). The average age was 72.7 years;
50.8% were female. Largest differences in co-morbidities
detected between PD patients and MC were: pathological frac-
tures (4.9% vs. 0.4%), heart murmurs (3.3% vs. 0.4%), frac-
tures of femur other than neck (2.9% vs. 0.4), spinal stenosis
(2.5% vs. 0.4%), hypercalcemia (1.6% vs. 0.4%), and bone neo-
plasms (7.8% vs. 2.5%), respectively. Annual per patient outpa-
